SCHEMBL430765

SCHEMBL430765

CCCOc1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.78
NR5A1 Q13285 1/20 0.66
MGAM O43451 4/20 0.55
GAA P10253 4/20 0.55
SI P14410 4/20 0.55
MGAM2 Q2M2H8 4/20 0.55
ABCG2 Q9UNQ0 1/20 0.54
ESR2 Q92731 1/20 0.54
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
ERN1 O75460 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ACACB O00763 1/20 0.49
ACACA Q13085 1/20 0.49
GPR84 Q9NQS5 1/20 0.49
RARB P10826 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20060978 0.94 LTA4H (0.70) LTA4HNR5A1MGAMGAASI
SCHEMBL20060977 0.94 LTA4H (0.70) LTA4HNR5A1MGAMGAASI
1-Hydroxy-4-Propoxybenzene SCHEMBL56796 0.94 LTA4H (0.88) LTA4HNR5A1MGAMGAASI
Sulfur Dioxide SCHEMBL21753700 0.93 LTA4H (0.68) LTA4HNR5A1MGAMGAASI
SCHEMBL428018 0.92 LTA4H (0.78) LTA4HNR5A1ABCG2ESR2CYP3A4
SCHEMBL10704665 0.91 LTA4H (0.84) LTA4HNR5A1MGAMGAASI
1-Hydroxy-4-Propoxybenzene SCHEMBL27539049 0.91 LTA4H (0.84) LTA4HNR5A1MGAMGAASI
SCHEMBL17108413 0.89 CYP3A4 (0.63) LTA4HGAACYP3A4CYP2D6MEN1
SCHEMBL9152649 0.89 CYP3A4 (0.63) LTA4HGAACYP3A4CYP2D6MEN1
SCHEMBL6836988 0.89 CYP3A4 (0.63) LTA4HGAACYP3A4CYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259491-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS Abbott Laboratories (US) 2002-11-27 EP claimed
WO-2001060802-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-08-23 WO claimed
CN-113574041-B Bisphenol production method and polycarbonate resin production method 三菱化学株式会社 2023-10-13 CN disclosed
CN-113574041-A Method for producing bisphenol and method for producing polycarbonate resin 三菱化学株式会社 2021-10-29 CN disclosed
WO-2020189201-A1 METHOD FOR PRODUCING BISPHENOL AND METHOD FOR PRODUCING POLYCARBONATE RESIN 三菱ケミカル株式会社 2020-09-24 WO disclosed
US-20120021190-A1 PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR FORMING SILICA COATING FILM, AND APPARATUS AND MEMBER EACH COMPRISING SILICA COATING FILM HITACHI CHEMICAL COMPANY, LTD. (JP) 2012-01-26 US disclosed
US-7534547-B2 Optically active compound and photosensitive resin composition OSAKA GAS COMPANY LIMITED (JP) 2009-05-19 US disclosed
US-7534547-B2 Optically active compound and photosensitive resin composition OSAKA GAS COMPANY LIMITED (JP) 2009-05-19 US disclosed
CN-1178906-C N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases ���Ͽع����޹�˾ 2004-12-08 CN disclosed
EP-1420771-A2 USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES Solvay Pharmaceuticals GmbH (DE) 2004-05-26 EP disclosed
EP-1375463-A1 OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION Kansai Research Institute, Inc. (JP) 2004-01-02 EP disclosed
US-20030211421-A1 Optically active compound and photosensitive resin composition KRI, INC. (JP) 2003-11-13 US disclosed
WO-2003007923-A2 USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES SOLVAY PHARMACEUTICALS GMBH (DE) 2003-01-30 WO disclosed
EP-1001930-B1 N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LAB (US) 2002-12-04 EP disclosed
EP-1259491-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS Abbott Laboratories (US) 2002-11-27 EP disclosed
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases DAVIDSEN STEVEN K (US) 2002-01-17 US disclosed
WO-2001060802-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-08-23 WO disclosed
CN-1261876-A N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases ABBOTT LAB (US) 2000-08-02 CN disclosed
EP-0422680-A2 Heat-sensitive recording sheet NIPPON PAPER INDUSTRIES CO., LTD. (JP) 1991-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007060-A1 Reverse hydroxamate inhibitors of matrix metalloproteinases MMP1, MMP9, MMP3 LTA4H 483/4885NR5A1 1048/4885MGAM 440/4885
US-20030211421-A1 Optically active compound and photosensitive resin composition ARCN1, RAD51, PAM LTA4H 1238/4885NR5A1 2224/4885MGAM 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.